Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance

BACKGROUND: Alectinib has shown a greater efficacy to ALK-rearranged non-small-cell lung cancers in first-line setting; however, most patients relapse due to acquired resistance, such as secondary mutations in ALK including I1171N and G1202R. Although ceritinib or lorlatinib was shown to be effectiv...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:EBioMedicine
Egile Nagusiak: Okada, Koutaroh, Araki, Mitsugu, Sakashita, Takuya, Ma, Biao, Kanada, Ryo, Yanagitani, Noriko, Horiike, Atsushi, Koike, Sumie, Oh-hara, Tomoko, Watanabe, Kana, Tamai, Keiichi, Maemondo, Makoto, Nishio, Makoto, Ishikawa, Takeshi, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier 2019
Gaiak:
Research paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6441848/
https://ncbi.nlm.nih.gov/pubmed/30662002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.01.019
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak